KAM
Krensavage Asset Management Portfolio holdings
AUM
$189M
This Quarter Return
-2.51%
1 Year Return
+19.71%
3 Year Return
+56.44%
5 Year Return
+120.01%
10 Year Return
+215.64%
AUM
$272M
AUM Growth
+$272M
(-14%)
Cap. Flow
-$28.6M
Cap. Flow
% of AUM
-10.53%
Top 10 Holdings %
Top 10 Hldgs %
99.2%
Holding
12
New
–
Increased
2
Reduced
10
Closed
–
Top Buys
| 1 |
Embecta
EMBC
|
$1.42M |
| 2 |
Enanta Pharmaceuticals
ENTA
|
$530K |
Top Sells
| 1 |
Regeneron Pharmaceuticals
REGN
|
$9.82M |
| 2 |
Alkermes
ALKS
|
$5.53M |
| 3 |
Cardinal Health
CAH
|
$5.42M |
| 4 |
Exelixis
EXEL
|
$5.12M |
| 5 |
Biogen
BIIB
|
$4.2M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
United Therapeutics
UTHR
$13.8B
| $45.5M | 16.73% | 201,222 -1,493 | -0.7% | -$337K |
|
|
2
Exelixis
EXEL
$10.1B
| $41.5M | 15.28% | 1,899,151 -234,552 | -11% | -$5.12M |
|
|
3
Biogen
BIIB
$19.4B
| $41.2M | 15.19% | 160,480 -16,346 | -9% | -$4.2M |
|
|
4
Regeneron Pharmaceuticals
REGN
$61.5B
| $38.9M | 14.32% | 47,256 -11,932 | -20% | -$9.82M |
|
|
5
Alkermes
ALKS
$4.78B
| $25.4M | 9.34% | 906,060 -197,391 | -18% | -$5.53M |
|
|
6
Cardinal Health
CAH
$35.5B
| $25.3M | 9.31% | 291,319 -62,395 | -18% | -$5.42M |
|
|
TARO
7
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
| $24.2M | 8.9% | 640,735 -2,345 | -0.4% | -$88.4K |
|
|
8
Embecta
EMBC
$847M
| $17.5M | 6.45% | 1,164,876 +94,066 | +9% | +$1.42M |
|
|
9
Enanta Pharmaceuticals
ENTA
$180M
| $8.21M | 3.02% | 735,103 +47,490 | +7% | +$530K |
|
|
EGRX
10
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $1.78M | 0.65% | 112,666 -771 | -0.7% | -$12.2K |
|
11
Vanda Pharmaceuticals
VNDA
$279M
| $1.56M | 0.57% | 360,429 -2,522 | -0.7% | -$10.9K |
|
12
Kodiak Sciences
KOD
$478M
| $616K | 0.23% | 342,312 -2,322 | -0.7% | -$4.18K |
|